ACTRN12611001270909Not yet recruitingPhase 4
Botulinum Toxin to treat vocal cord dysfunction in severe asthma
Prof Philip Bardin0 sites46 target enrollmentStarted: December 12, 2011Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 46
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Treatment
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (—)
- Sex
- All
Inclusion Criteria
- •Asthma confirmed by airway reversibility (FEV1 >12% and 200mls) OR airway hyperreponsiveness;
- •Subjects with clinical features of severe refractory asthma;
- •Subjects with well documented requirement for regular treatment with high dose ICS;
- •Subjects with well documented requirement for controller medication in addition to high dose ICS;
- •Evidence of optimal medication use;
- •Sub-optimally controlled asthma, as indicated by ACT score <15;
- •Post-bronchodilator FEV1 >40% predicted;
- •VCD demonstrated by 320-slice CT larynx (RATIO below LLN during either inspiration or expiration;
Exclusion Criteria
- •Other significant respiratory disorder;
- •Known vocal cord pathology or diagnosed voice condition other than VCD;
- •Known brain or brainstem cancer, or head and neck cancer;
- •Known neurological disorders or neuromuscular disorders;
Investigators
Similar Trials
Completed
Not Applicable
Botulinum toxin injection for vocal cord dysfunction in asthmaVocal cord dysfunctionRespiratory - AsthmaAsthmaACTRN12613000455763Monash Medical Centre12
Completed
Not Applicable
Botulinum toxin in the treatment of orofacial tardive dyskinesias: a single blind studyTardive dyskinesiaDystoniaISRCTN81508784Parnassia Psycho-medical Centre (Netherlands)14
Active, not recruiting
Phase 1
Block of the neural structure otic ganglion in patients with chronic cluster headacheCluster headacheEUCTR2016-004213-28-NODepartment of Neuroscience, NT10
Active, not recruiting
Not Applicable
Behandling med botulinumtoxin vid neurogen blåsfunktionsstörningThe trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as behavioral techniques, physiotherapy, intermittent catheterisation or pharmacotherapy.EUCTR2005-003068-47-SERegion Skåne, Universitetssjukhuset i Lund, Urologiska kliniken40
Active, not recruiting
Not Applicable
Botulinum toxin treatment in hyperhidrosis (excessive sweating).Hyperhidrosis-craniofacial, inguinal, palmar, plantar and truncal.MedDRA version: 17.1Level: PTClassification code 10020642Term: HyperhidrosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-003132-30-SESvettmottagningen Hidroskliniken, Stockholm